Mirati’s Krazati Is Second KRAS Inhibitor To Market, But At Higher Price
Confirmatory Trial Seeks To Show Survival Advantage
Krazati was approved for second-line NSCLC with labeling that positions it ahead of Lumakras on efficacy, but not safety. Pricing is slightly higher than for Amgen’s drug.
You may also be interested in...
The Japanese drug maker gave multiple presentations on AstraZeneca-partnered Enhertu and other deruxtecan-based ADCs. Plus Gilead presented data on Trodelvy, Amgen showed early frontline data for Lumakras, and J&J’s EGFR-directed bispecific Rybrevant showed a 50% ORR in heavily pretreated patients.
A Phase I study showed better response and survival rates than Amgen’s Lumakras and Mirati’s Krazati, but investigators said confirmation from larger trials is needed.
Novartis revealed detailed terms and a 4 October spin-off date for Sandoz’s standalone debut. Also, MIRA launched a small IPO, but two firms plan to go public in SPAC mergers. Also, Mirati’s $345m offering leads follow-ons offerings and Sangon Biotech raised $290m in venture capital.